Imidazo[1,2-a]pyrazines 154 described above [87] have been tested by the same authors against cyclin-dependent kinase-9 (CDK9), a molecular target for the treatment of various malignant cancers, responsible for the cell cycle control and the promotion of cancer initiation as well as progression [88]. Here, CDK9 is linked to cancer.